Literature DB >> 30982216

Identification of eleven different mutations including six novel, in the arylsulfatase B gene in Iranian patients with mucopolysaccharidosis type VI.

Rokhsareh Jafaryazdi1, Sedigheh Shams2,3,4, Anna Isaian2,3, Aria Setoodeh5, Shahram Teimourian6.   

Abstract

Mucopolysaccharidosis VI is a rare autosomal recessive disorder caused by the deficiency of enzyme Arylsulfatase B. The enzyme deficiency leads to the accumulation of dermatan sulfate in connective tissue which causes manifestations related to MPS VI. Up to now, three different disease causing variants are reported in Iranian patients. In this study, we scanned ARSB gene of 13 Iranian patients from 12 families in whom all parents were consanguineous and from the same ethnicity except one family that were not consanguineous but co-ethnic. We found six not previously reported disease causing variants. We extracted DNA from peripheral blood samples of patients that were previously confirmed as MPS VI by clinical, biochemical and enzymatic assays including berry-spot test and fluorimetry, followed by PCR and direct sequencing. Computational approaches were used to analyze novel variants in terms of their impact on the protein structure. 11 disease causing variants and 15 polymorphisms were found. Six disease causing variants were novel and five were previously reported of which three were in Iranian population. Four of patients, who were unrelated, two by two had the same disease causing variant and polymorphisms, which indicates a possible founder effect. Our study also implicates genotype-phenotype correlation. Computational structural modeling indicated these disease causing variants might affect structural stability and function of the protein. Data of this study confirms the existence of mutational heterogeneity in the ARSB between Iranian patients. Disease causing variants with high frequency can be used in the prenatal diagnosis and genetic counseling. Also, the existence of the same variants and polymorphisms in some of the unrelated patients indicates a possible founder effect.

Entities:  

Keywords:  Arylsulfatase B; In silico; Iran; MPS VI; Sanger sequencing; Variant

Mesh:

Substances:

Year:  2019        PMID: 30982216     DOI: 10.1007/s11033-019-04804-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  39 in total

1.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

Review 2.  Overview of the mucopolysaccharidoses.

Authors:  Joseph Muenzer
Journal:  Rheumatology (Oxford)       Date:  2011-12       Impact factor: 7.580

3.  Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase.

Authors:  T Litjens; E G Baker; K R Beckmann; C P Morris; J J Hopwood; D F Callen
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

Review 4.  Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature.

Authors:  V I Vougioukas; A Berlis; M V Kopp; R Korinthenberg; J Spreer; V van Velthoven
Journal:  Pediatr Neurosurg       Date:  2001-07       Impact factor: 1.162

5.  Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy.

Authors:  Litsa Karageorgos; Doug A Brooks; Paul Harmatz; David Ketteridge; Anthony Pollard; Elizabeth L Melville; Emma Parkinson-Lawrence; Peter R Clements; John J Hopwood
Journal:  Mol Genet Metab       Date:  2006-12-11       Impact factor: 4.797

6.  Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  Stuart J Swiedler; Michael Beck; Manal Bajbouj; Roberto Giugliani; Ida Schwartz; Paul Harmatz; James E Wraith; Jane Roberts; David Ketteridge; John J Hopwood; Nathalie Guffon; M Clara Sá Miranda; Elisa Leão Teles; Kenneth I Berger; Cheri Piscia-Nichols
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

7.  Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests.

Authors:  Paulina Mabe; Alf Valiente; Vivian Soto; Verónica Cornejo; Erna Raimann
Journal:  Clin Chim Acta       Date:  2004-07       Impact factor: 3.786

8.  Mutational analysis of 105 mucopolysaccharidosis type VI patients.

Authors:  Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood
Journal:  Hum Mutat       Date:  2007-09       Impact factor: 4.878

9.  Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces.

Authors:  Hanka Venselaar; Tim A H Te Beek; Remko K P Kuipers; Maarten L Hekkelman; Gert Vriend
Journal:  BMC Bioinformatics       Date:  2010-11-08       Impact factor: 3.169

10.  Family study of a novel mutation of mucopolysaccharidosis type VI with a severe phenotype and good response to enzymatic replacement therapy: Case report.

Authors:  Myriam Ley-Martos; Juan M Guerrero; Marta Lucas-Javato; Cristina Remón-García; J Raúl García-Lozano; Cristóbal Colón; Pablo Crujeiras; Daniel Rodrigues; Pedro Paúl-Sánchez; Hada C Macher
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more
  2 in total

1.  Whole exome sequencing revealed a novel homozygous variant in the DGKE catalytic domain: a case report of familial hemolytic uremic syndrome.

Authors:  Soraya Gholizad-Kolveiri; Nakysa Hooman; Rasoul Alizadeh; Rozita Hoseini; Hasan Otukesh; Saeed Talebi; Mansoureh Akouchekian
Journal:  BMC Med Genet       Date:  2020-08-24       Impact factor: 2.023

Review 2.  Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.

Authors:  Francesca D'Avanzo; Alessandra Zanetti; Concetta De Filippis; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.